Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Onkure Therapeutics Inc OKUR

Healthcare Biotechnology
OnKure Therapeutics, Inc., formerly Reneo Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a robust pipeline of tumor-agnostic candidates. The Company is developing OKI-219, a selective PI3KaH1047R inhibitor, as its lead program. OKI-219 is being evaluated in a Phase I clinical trial in solid tumor patients with PI3KaH1047R mutations, including breast cancer. The Company is also focused on targeting oncogenic PI3Ka and has multiple programs designed to enable targeting of this key oncogene.


NDAQ:OKUR - Post by User

Onkure Therapeutics Inc
Bullboard Posts
Next >>
User Avatar Image
(233)
•••
Post by whytestockson Jun 14, 2024 11:45pm
102 Views
Post# 36090289

Kuehn Law Encourages BATL, DRQ, PRFT, and RPHM Investors to

Kuehn Law Encourages BATL, DRQ, PRFT, and RPHM Investors to
Breaking News: $RPHM Kuehn Law Encourages BATL, DRQ, PRFT, and RPHM Investors to Contact Law Firm | BenzingaNEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the...RPHM - Kuehn Law Encourages BATL, DRQ, PRFT, and RPHM Investors to Contact Law Firm | Benzinga


Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities